Figure 4

The expression of GFAP in the spinal cords. (A,B) Contrasting to the control, the level of GFAP in the model group significantly increased (#P << 0.01). After UCMSC-SPK1 treatment, the expression of GFAP obviously decreased (**P < 0.05), significantly difference was found in GFAP expression between the UCMSC-SPK1 and UCMSC group (@P < 0.05). (C,D) The western blot results indicated that GFAP expression tendency was consistent with that of the immunohistochemistry results.